Kinnate Biopharma, Inc. (KNTE)
| Market Cap | 1.09B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 43.68M |
| EPS (ttm) | -2.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,526,237 |
| Open | 24.33 |
| Previous Close | 24.17 |
| Day's Range | 23.50 - 25.71 |
| 52-Week Range | 17.58 - 48.75 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 51.00 (+115.3%) |
| Est. Earnings Date | Nov 15, 2021 |
About KNTE
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. It develops KIN-2787, which is a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for KNTE stock is "Buy." The 12-month stock price forecast is 51.00, which is an increase of 115.28% from the latest price.
News
Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results
Announced first patient dosed in Phase 1 trial evaluating KIN-2787 in patients with BRAF mutation-positive solid tumors
Should You Buy Kinnate Biopharma (KNTE) Ahead of Earnings?
Kinnate Biopharma (KNTE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.
Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021
SAN FRANCISCO and SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...
Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors
Accomplished immunologist and veteran biopharma executive has extensive experience in advancing pre-clinical stage oncology programs into the clinic Accomplished immunologist and veteran biopharma execu...
Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expa...
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team
Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021
Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class I, Class II and Class III BRAF mutations Data highlights in vitro and in vivo activity of KIN-2787 against...
Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference
SAN FRANCISCO and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule ki...
Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture
SAN FRANCISCO and SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule ki...
Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting
SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)---- $KNTE #ASCO--Data highlights pre-clinical activity of KIN-2787 in Class II and Class III BRAF-mutant models
Kinnate Biopharma Inc. Announces the Departure of Dr. Stephen Kaldor from its Board of Directors
SAN FRANCISCO and SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule ...
Kinnate Biopharma Inc. Reports Full Year 2020 Financial Results
Completed recent IPO, raising $276MM in gross proceeds to fund kinase inhibitors for genomically defined cancers
Kinnate Biopharma Inc. Announces Its Addition to the Russell 2000® Index
SAN FRANCISCO and SAN DIEGO, March 19, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule ...
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
SAN FRANCISCO and SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...
Why These 4 Health Care Stocks Are Moving Today
Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple scleros...
Why SVB Leerink Is Bullish On Kinnate Biopharma
Kinnate Biopharma Inc (NASDAQ: KNTE), which focuses on developing small-molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, recently raised $276 million in gross proceeds in ...
Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Pu...
SAN FRANCISCO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...
U.S. IPO Weekly Recap: The IPO Market Is Taught A Thing Or Two In An 8 IPO Week
The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education & Technology Group. Two companies, Ondas and AMMO Inc., ...
KNTE Stock: 13 Things to Know About the Kinnate Biopharma IPO
KNTE stock has rocketed higher by as much as 115% following the Kinnate Biopharma IPO. Here's what you should know right now.
Kinnate Biopharma stock more than doubles in trading debut
Kinnate Biopharma shares more than doubled in their trading debut Thursday, after the company upsized its initial public offering and priced it above its proposed range. The stock, trading on Nasdaq und...
Kinnate Biopharma Stock Doubles As IPO Begins Trading
Kinnate Biopharma is a preclinical biotech focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat cancers. The IPO raised $240 million.
Kinnate Biopharma upsizes IPO and prices above range at $20 a share
Kinnate Biopharma upsized its initial public offering on Wednesday and priced it at $20 a share, above its $18 to $19 proposed price range. The company sold 12 million shares, or more than the 11.5 mill...
Kinnate Biopharma Announces Pricing of Initial Public Offering
SAN FRANCISCO and SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule k...
Kinnate Biopharma to offer 11.5 million shares in planned IPO, priced at $18 to $19 each
Kinnate Biopharma set terms for its initial public offering on Wednesday with plans to offer 11.5 million shares priced at $18 to $19 each. The company would raise $218.5 million at the top of that range.
IPO Preview: Kinnate Biopharma Commences $100 Million IPO
The firm is developing treatments for various cancers using a kinase inhibitory approach.